Eventide Asset Management - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$18,905,365
+16.8%
716,927
-23.8%
0.34%
+24.1%
Q2 2023$16,188,227
+3.7%
941,1760.0%0.27%
-4.2%
Q1 2023$15,604,698
-64.1%
941,176
+32.2%
0.29%
-50.9%
Q2 2021$43,416,000
-1.0%
712,1970.0%0.58%
-10.3%
Q1 2021$43,871,000712,1970.65%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$100,609,51348.41%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$514,990,89915.50%
M28 Capital Management LP 304,700$5,051,9265.71%
Cormorant Asset Management, LP 4,557,414$75,5624.98%
Octagon Capital Advisors LP 1,338,160$22,186,6933.19%
Ikarian Capital, LLC 594,686$9,859,8942.24%
Affinity Asset Advisors, LLC 389,800$6,462,8842.13%
VIKING GLOBAL INVESTORS LP 26,620,991$441,376,0312.07%
Ikarian Capital, LLC 549,600$9,112,3682.07%
Affinity Asset Advisors, LLC 320,000$5,305,6001.75%
View complete list of BRIDGEBIO PHARMA INC shareholders